SINTX guides Q3-Q4 2026 revenue of $0.9M-$1.3M per quarter; $3.2M industrial orders

Sintx Technologies, Inc.

2026-Q2 EPS reported -$1.46 revenue$832,000

Q3 2026 revenue guided to $0.9M-$1.1M; Q4 2026 to $1.0M-$1.3M, subject to delivery and customer acceptance.
Received ~$3.2M in H1 2026 industrial purchase orders from contract manufacturers; revenue recognition expected from Q3 2026.
SiNAPTIC Foot & Ankle Wedge System (FDA 510(k) cleared Oct 2025) in Limited Use Release; 12 independent orthopedic distributors engaged.
Q2 2026 financing raised ~$5.0M gross via private placement and ATM facility to fund commercialization and operations.
NIH granted 12-month extension to access ~$745K remaining on $1.97M grant for porous SiN/PEEK spinal implant development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.